Diclorhidrato De Trimetazidina shortage — PE supply status & alternatives

Diclorhidrato De Trimetazidina

—

In supply · Australia

Vastarel Mr

In supply · 🇦🇺 Australia · short in🌐 PE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Diclorhidrato De Trimetazidina
Brand names	Vastarel Mr
Therapeutic category	Auto-created by DIGEMID — Discontinuidad de Medicamentos (Peru) scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 3 resolved events

◷

2–9 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🌐

DIGEMID · 1h ago

Medium

Verified timeline regulator events

🌐 9 Dec 2025

medium reported

🌐 8 Apr 2025

Shortage resolved

🌐 1 Apr 2025

medium reported

🌐 28 Jan 2025

medium reported

🌐 20 Jan 2025

Shortage resolved

🌐 5 Sept 2024

medium reported

Sources official regulators

🌐

DIGEMID

verified 1h ago

verify ↗

Mederti Drug Report

Generated 5 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.